Merck & Co. Inc.’s experimental treatment vericiguat being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2019-11-18 06:57:572019-11-18 13:01:18Merck and Bayer's heart drug meets main study goal
